kreon 5 000 ph.eur.e. gastrorezistentna zrnca
mylan healtcare gmbh - amilaza; lipaza; proteaza - gastrorezistentna zrnca - amilaza 3600 ph.eur. e. / 1 vsebnik lipaza5000 ph.eur. e. / 1 vsebnik proteaza200 ph.eur. e. / 1 vsebnik; lipaza 5000 ph.eur. e. / 1 vsebnik proteaza200 ph.eur. e. / 1 vsebnik; proteaza 200 ph.eur. e. / 1 vsebnik - multiencimska zdravila (lipaze, proteaze)
pankreatin krka trde kapsule
krka, d.d., novo mesto - amilaza, lipaza, proteaza - kapsula, trda - amilaza 7200 ph.eur. e. / 1 kapsula; lipaza 10000 ph.eur. e. / 1 kapsula; proteaza 400 ph.eur. e. / 1 kapsula - multiencimska zdravila (lipaze, proteaze)
lorviqua
pfizer europe ma eeig - lorlatinib - karcinom, pljučni pljuč - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. glej poglavja 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
panzynorm forte filmsko obložene tablete
krka, d.d., novo mesto - amilaza; lipaza; proteaza - filmsko obložena tableta - amilaza 12000 ph.eur. e. / 1 tableta lipaza20000 ph.eur. e. / 1 tableta proteaza900 ph.eur. e. / 1 tableta; lipaza 20000 ph.eur. e. / 1 tableta proteaza900 ph.eur. e. / 1 tableta; proteaza 900 ph.eur. e. / 1 tableta - multiencimska zdravila (lipaze, proteaze)
panzynorm forte filmsko obložene tablete
krka, d.d., novo mesto - amilaza; lipaza; proteaza - filmsko obložena tableta - amilaza 12000 ph.eur. e. / 1 tableta lipaza20000 ph.eur. e. / 1 tableta proteaza900 ph.eur. e. / 1 tableta; lipaza 20000 ph.eur. e. / 1 tableta proteaza900 ph.eur. e. / 1 tableta; proteaza 900 ph.eur. e. / 1 tableta - multiencimska zdravila (lipaze, proteaze)
panzynorm forte filmsko obložene tablete
krka, d.d., novo mesto - amilaza; lipaza; proteaza - filmsko obložena tableta - amilaza 12000 ph.eur. e. / 1 tableta lipaza20000 ph.eur. e. / 1 tableta proteaza900 ph.eur. e. / 1 tableta; lipaza 20000 ph.eur. e. / 1 tableta proteaza900 ph.eur. e. / 1 tableta; proteaza 900 ph.eur. e. / 1 tableta - multiencimska zdravila (lipaze, proteaze)
panzynorm forte filmsko obložene tablete
krka, d.d., novo mesto - amilaza; lipaza; proteaza - filmsko obložena tableta - amilaza 12000 ph.eur. e. / 1 tableta lipaza20000 ph.eur. e. / 1 tableta proteaza900 ph.eur. e. / 1 tableta; lipaza 20000 ph.eur. e. / 1 tableta proteaza900 ph.eur. e. / 1 tableta; proteaza 900 ph.eur. e. / 1 tableta - multiencimska zdravila (lipaze, proteaze)
panzynorm forte filmsko obložene tablete
krka, d.d., novo mesto - amilaza; lipaza; proteaza - filmsko obložena tableta - amilaza 12000 ph.eur. e. / 1 tableta lipaza20000 ph.eur. e. / 1 tableta proteaza900 ph.eur. e. / 1 tableta; lipaza 20000 ph.eur. e. / 1 tableta proteaza900 ph.eur. e. / 1 tableta; proteaza 900 ph.eur. e. / 1 tableta - multiencimska zdravila (lipaze, proteaze)
glybera
uniqure biopharma b.v. - alipogen tiparvovec - hiperlipoproteinemija tipa i - sredstva za spreminjanje lipidov - zdravilo glybera je indicirano za odrasle bolnike z diagnozo familialne lipoproteinske lipaze (lpld) in hude ali večkratne napade pankreatitisa, čeprav omejitve maščobnih maščob. diagnozo lpld je treba potrditi z genetskim testiranjem. indikacija je omejena na bolnike z zaznavnimi nivoji beljakovin lpl.